“We made significant clinical and regulatory progress in the third quarter,” said Brian Sullivan, CEO and co-founder of Celcuity (CELC). “At the ESMO Congress, we presented potentially practice-changing safety and efficacy results for the gedatolisib regimens from the PIK3CA wild-type cohort of our Phase 3 VIKTORIA-1 trial at a late breaking oral presentation. We remain on track to submit the New Drug Application for gedatolisib later this year based on data from the PIK3CA wild-type cohort. The PIK3CA mutant cohort of the Phase 3 VIKTORIA-1 clinical trial is fully enrolled with topline data expected in late Q1 2026 or during Q2 2026.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CELC:
- Is CELC a Buy, Before Earnings?
- Short Report: AST SpaceMobile bears return after violent squeeze
- Celcuity Inc.’s Promising Phase 3 Breast Cancer Study: A Market Game-Changer?
- Celcuity’s Phase 3 Breast Cancer Study: A Potential Game-Changer?
- Celcuity Inc.’s Promising Study on mCRPC Treatment: Key Insights for Investors